Prevention of antibiotic-associated diarrhea in children by Clostridium butyricum MIYAIRI

Pediatr Int. 2003 Feb;45(1):86-90. doi: 10.1046/j.1442-200x.2003.01671.x.


Background: Clostridium butyricum MIYAIRI (CBM) is a probiotic bacteria used for anti-diarrheal medicine in Japan. The preventive effect of CBM was investigated for antibiotic-associated diarrhea (AAD) in children.

Methods: One hundred and ten children who suffered from upper respiratory tract infection or gastroenteritis were divided into three groups. Twenty-seven of the patients received only antibiotics, 38 received CBM from the mid point of the antibiotic treatment and 45 concomitantly received CBM from the beginning of the antibiotic treatment. To examine the effects of CBM on AAD, the changes in intestinal flora were investigated.

Results: Diarrhea was observed in 59% of the subjects who received only antibiotics, and total fecal anaerobes, especially Bifidobacterium, were remarkably decreased. In contrast, diarrhea in the subjects who received CBM from either the middle or the beginning of the antibiotic therapy was decreased to 5% and 9%, respectively. Concomitant administration of CBM increased anaerobes and prevented the decrease of Bifidobacterium in the subjects who received antibiotics.

Conclusions: Clostridium butyricum MIYAIRI is effective for both the treatment and the prophylaxis of AAD in children, as it normalizes the intestinal flora disturbed by antibiotics.

MeSH terms

  • Anti-Bacterial Agents / adverse effects
  • Child
  • Child, Preschool
  • Clostridium*
  • Diarrhea / microbiology
  • Diarrhea / prevention & control*
  • Female
  • Humans
  • Infant
  • Male
  • Probiotics / therapeutic use*


  • Anti-Bacterial Agents